Strongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology
“As a company passionately working to accelerate development of its rare endocrine disease franchise, we were pleased to participate in the exchange of exciting new research findings for the rare disease community at the
COR-003, Strongbridge’s lead product candidate, is a cortisol synthesis inhibitor currently being studied in the global Phase 3 SONICS trial for the treatment of endogenous Cushing's syndrome. COR-005 is a next-generation somatostatin analog (SSA) with a unique receptor binding and activation profile to somatostatin receptor subtypes, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors.
“Treating rare diseases like Cushing’s syndrome and acromegaly are fraught with challenges and limitations. In fact, nearly 80 percent of acromegaly patients are not well controlled on existing first-line therapy alone and up to 20 percent may have not have a response at all,” said
Poster Presentation Details:
- Guided Poster #123 (Neuroendocrinology) – A placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects;
Klaus Kutz ;Sunday, May 29, 2016 –13:15-14:15 GMT
- Guided Poster #158 (Pituitary Clinical 1) – Differentiated pharmacokinetics of levoketoconazole (COR-003), the single 2S,4R-enantiomer of ketoconazole, a new investigational drug for the treatment of Cushing’s syndrome;
Ruth Thieroff-Ekerdt ;Monday, May 30, 2016 –13:15-14:15 GMT
- ePoster #699 – A placebo-controlled study of repeated subcutaneous doses of COR-005 alone or with octreotide on GHRH-stimulated GH and pharmacokinetics in healthy male subjects;
Klaus Kutz
About
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements. These statements relate to future events and involve known and unknown risks, including, without limitation, uncertainties regarding Strongbridge's strategy, plans, outcomes of product development efforts, costs and results, future financial position and objectives of management for future operations. The words "anticipate," "estimate," "expect," "intend," "may," "plan," "potential," "project," "target," "will," "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and
Contacts: Corporate and Media Relations Elixir Health Public RelationsLindsay M. Rocco +1 862-596-1304 [email protected] Investor RelationsThe Trout Group Marcy Nanus +1 646-378-2927 [email protected]USA 900 Northbrook Drive Suite 200Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389